Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Edwards Lifesciences Corp

NYSE: EW · Industrial Applications and Services · 6 alerts · CIK 1099800

Share price
$107.11Close, Nov 16
Market cap
$61.6B
Shares outstanding
575MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Edwards Lifesciences Corp filings on SEC EDGAR ↗

4:52 PM ET Form 4
Insider Selling

Edwards Lifesciences Cvp, Tavr Daniel J. Lippis Sells $64.5K of Stock

Daniel J. Lippis, Cvp, Tavr, sold 619 shares of Edwards Lifesciences Corp at $104.25 a share, worth $64.5K in total on Nov 10, 2026. Shares held after the trade: 40,034 (-1.5%).

Value
$64.5K
Shares
619
Price
$104.25
Role
Cvp, Tavr
Holding change
-1.5%
Trade date
Nov 10, 2026
4:29 PM ET Form 4
Insider Selling

Edwards Lifesciences CVP,Strategy/Corp Development Donald E. Bobo Jr. Sells $5.04M of Stock

Donald E. Bobo Jr., CVP,Strategy/Corp Development, sold 48,900 shares of Edwards Lifesciences Corp at $103.05 a share, worth $5.04M in total on Nov 9, 2026. Shares held after the trade: 22,798 (-68.2%).

Value
$5.04M
Shares
48,900
Price
$103.05
Role
CVP,Strategy/Corp Development
Holding change
-68.2%
Trade date
Nov 9, 2026
4:29 PM ET Form 4
Insider Selling

Edwards Lifesciences CEO Bernard J. Zovighian Sells $2.38M of Stock

Bernard J. Zovighian, CEO, sold 23,100 shares of Edwards Lifesciences Corp at $102.78 to $103.39 a share (average $103.02) in 2 transactions, worth $2.38M in total on Nov 9, 2026. Shares held after the trade: 98,845 (-12.3%).

Value
$2.38M
Shares
23,100
Average price
$103.02
Role
CEO
Holding change
-12.3%
Trade date
Nov 9, 2026
4:25 PM ET 10-Q
Financial Results

Edwards Lifesciences Q3 2026 Results: Net Income $308M, Up 5.6% YoY

For the nine months ended September 30, 2026, Edwards Lifesciences reported net sales of $5.11 billion, a 13.5% increase over the prior year. Despite higher revenue, net income attributable to the corporation decreased to $930.1 million from $982.3 million, primarily due to a significant $163.6 million impairment loss and higher income tax provisions.

Key figure
Net income $308M · +5.6% YoY
4:22 PM ET 8-K
Financial Results

Edwards Lifesciences Financial Results

Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing 11.2% constant currency growth driven by strong performance in TAVR and TMTT segments. Based on the results, the company raised its full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05.

Term
3 years

“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.”

Bernard Zovighian, CEO of Edwards Lifesciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.